Investigational New Drugs

, Volume 25, Issue 3, pp 237–245 | Cite as

Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers

  • Sanjay GoelEmail author
  • Kavita Desai
  • Sirisha Karri
  • Radharani Gollamudi
  • Imran Chaudhary
  • Anca Bulgaru
  • Andreas Kaubisch
  • Gary Goldberg
  • Mark Einstein
  • Fernando Camacho
  • Sharyn Baker
  • Sridhar Mani
Phase I Studies


Background: Capecitabine and irinotecan have demonstrated in vitro synergistic anti-cancer activity, and both are substrates for carboxyl esterases (CES). We conducted a study to identify a safe dose and potential drug-drug interactions of this combination.

Methods: This was an open-label phase I dose escalation trial. Irinotecan was given as a 30 min infusion on days 1 and 8, and capecitabine on days 1–14 of a 21-day cycle. Plasma for pharmacokinetic analyses was drawn on days 1 and 8.

Results: Forty-seven patients with advanced solid tumors received 202 cycles of chemotherapy in 6 dose cohorts. At the highest dose tested, 1 of 3 patients developed fatal neutropenia and gram-negative sepsis. At dose level 5 (100/2000), 2 of 28 patients developed cycle 1 DLT—grade 3 diarrhea/vomiting, and grade 3 diarrhea. Responses were observed in 9 of 35 (5 of 9 ovarian cancer) evaluable patients. The AUC(0-last) of irinotecan, SN-38G, and APC were similar on days 1 and 8. However, SN-38 Tmax was longer on Day 8 (0.88 h vs. 1.23 h, p = 0.012). While SN-38 AUC(0-last) was lower on day 8 by 35%, this was not statistically significant (p = 0.123).

Conclusions: Capecitabine results in a significantly delayed conversion of irinotecan to SN-38, suggesting drug-drug interaction at the level of CES. This suggests caution should be used when irinotecan is combined with substrates of CES, and warrants further study. The combination of irinotecan and capecitabine is safe and well tolerated at 100/2000, and warrants further evaluation in ovarian and breast cancer.


Pharmacokinetics Phase I Irinotecan Capecitabine Solid tumors 



This study is supported by a grant from Hoffmann-La Roche Inc and Pfizer Inc. SM is supported by a clinical investigator award from the Damon Runyon Cancer Research Foundation (CI: 15-02). ME is supported by a Clinical Mentored Research Scholar Program Award (K12 RR017672).


  1. 1.
    Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan study group. N Engl J Med 343:905–914PubMedCrossRefGoogle Scholar
  2. 2.
    Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047PubMedCrossRefGoogle Scholar
  3. 3.
    Pentheroudakis G, Twelves C (2002) The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 22:3589–3596PubMedGoogle Scholar
  4. 4.
    Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297PubMedCrossRefGoogle Scholar
  5. 5.
    O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823PubMedCrossRefGoogle Scholar
  6. 6.
    Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, Xeloda Colorectal Cancer Study Group (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106PubMedGoogle Scholar
  7. 7.
    Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292PubMedGoogle Scholar
  8. 8.
    Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704PubMedCrossRefGoogle Scholar
  9. 9.
    Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23–44PubMedCrossRefGoogle Scholar
  10. 10.
    Nishimura G, Fujita H, Ninomiya I, Fushida S, Fujimura T, Ohta T (2006) Evidence of increased effect of thymidine phosphorylase by irinotecan: a proof for the intensified efficacy by combination with irinotecan and capecitabine. In: Proceedings of the 2006 Gastrointestinal Cancers Symposium (abstract # 298)Google Scholar
  11. 11.
    Cao S, Durrani FA, Rustum YM (2005) Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer 4:336–343PubMedCrossRefGoogle Scholar
  12. 12.
    Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, Mery-Mignard D, Cornen X, Mouri Z, Bugat R (2005) A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer 92:820–826PubMedCrossRefGoogle Scholar
  13. 13.
    Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16:1123–1132PubMedCrossRefGoogle Scholar
  14. 14.
    Czejka M, Schueller J, Hauer K, Ostermann E (2005) Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer. Anticancer Res 25:2985–2990PubMedGoogle Scholar
  15. 15.
    Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ (2006) A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 94:964–968PubMedCrossRefGoogle Scholar
  16. 16.
    Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038–2043Google Scholar
  17. 17.
    Perry MC (2006) Reponses to Topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes? J Clin Oncol 24:1980–1981PubMedCrossRefGoogle Scholar
  18. 18.
    Omura GA (2003) Modified Fibonacci search. J Clin Oncol 21:3177PubMedCrossRefGoogle Scholar
  19. 19.
    Package insert: Irinotecan. Downloaded Aug 7, 2006Google Scholar
  20. 20.
    Product Monograph data on file with Hoffman La Roche, Nutley, NJ, 2004Google Scholar
  21. 21.
    CTC version 2.0. Scholar
  22. 22.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRefGoogle Scholar
  23. 23.
    de Bruijn P, Willems EW, Loos WJ, Verweij J, Sparreboom A (2004) Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples. Anal Biochem 328:84–86PubMedCrossRefGoogle Scholar
  24. 24.
    Hamberg P, Donders RC, ten Bokkel Huinink D (2006) Central nervous system toxicity induced by irinotecan. J Natl Cancer Inst 98:219lGoogle Scholar
  25. 25.
    Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M (2002) Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 13:797–801PubMedCrossRefGoogle Scholar
  26. 26.
    Cardinale D, Colombo A, Colombo N (2006) Acute coronary syndrome induced by oral capecitabine. Can J Cardiol 22:251–253PubMedGoogle Scholar
  27. 27.
    Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S (2002) Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol 25:528–534PubMedCrossRefGoogle Scholar
  28. 28.
    Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM (2003) Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21:291–297PubMedCrossRefGoogle Scholar
  29. 29.
    Rischin D, Phillips KA, Friedlander M, Harnett P, Quinn M, Richardson G, Martin A (2004) A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol Oncol 93:417–421PubMedCrossRefGoogle Scholar
  30. 30.
    Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895–904PubMedCrossRefGoogle Scholar
  31. 31.
    Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130–2140Google Scholar
  32. 32.
    Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801–3807PubMedGoogle Scholar
  33. 33.
    Goel S, Bulgaru A, Hochster H, Wadler S, Zamboni W, Egorin M, Ivy P, Leibes L, Muggia F, Lockwood G, Harvey E, Renshaw G, Mani S (2003) Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. Ann Oncol 14:1682–1687PubMedCrossRefGoogle Scholar
  34. 34.
    Gold PJ, Godfrey T, Dhami M, Andria M, Fischer D, Chen Y-M, Samid D, Meropol N (2003) Capecitabine and Irinotecan as 1st line therapy for patients with metastatic colorectal cancer. Phase II study preliminary results. In: Proceedings of the 39th annual meeting of the American society of clinical oncology 22:2003 (abstract 1158)Google Scholar
  35. 35.
    Grothey K, Jordan O, Kellner C, Constantin G, Dittrich H, Kroening L, Mantovani C, Schlichting H, Forstbauer H-J, (2003) Schmoll Randomized Phase II trial of capecitabine plus irinotecan (capiri) vs capecitabine plus oxaliplatin (capox) as first line therapy of advanced colorectal cancer (ACRC). In: Proceedings of the 39th annual meeting of the American society of clinical oncology 22:2003 (abstract 1022)Google Scholar
  36. 36.
    Tabata T, Katoh M, Tokudome S, Nakajima M, Yokoi T (2004) Identification of the cytosolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab Dispos 32:1103–1110PubMedCrossRefGoogle Scholar
  37. 37.
    Sanghani SP, Quinney SK, Fredenburg TB, Sun Z, Davis WI, Murry DJ, Cummings OW, Seitz DE, Bosron WF (2003) Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 9:4983–4991PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Sanjay Goel
    • 1
    • 2
    Email author
  • Kavita Desai
    • 1
    • 2
  • Sirisha Karri
    • 1
    • 2
  • Radharani Gollamudi
    • 1
    • 2
  • Imran Chaudhary
    • 1
    • 2
  • Anca Bulgaru
    • 1
    • 2
  • Andreas Kaubisch
    • 1
    • 2
  • Gary Goldberg
    • 1
    • 3
  • Mark Einstein
    • 1
    • 3
  • Fernando Camacho
    • 2
  • Sharyn Baker
    • 4
  • Sridhar Mani
    • 1
    • 2
  1. 1.Department of OncologyAlbert Einstein College of Medicine and Cancer CenterBronxUSA
  2. 2.Department of OncologyMontefiore Medical CenterNYUSA
  3. 3.Division of Gynecologic OncologyMontefiore Medical CenterBronxUSA
  4. 4.Department of OncologyJohns Hopkins University, School of MedicineBaltimoreUSA

Personalised recommendations